ExagenXGN -3.40%60 Days Payable is 53.41 as of Mar. 2026, which is 9% above its 10-year median of 49.16. GuruFocus rates XGN with a GF Score™ of 60/100 and a GF Value™ of $3.00 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Exagen ranks worse than 63.16% on this metric.
Exagen's average Accounts Payable for the
three
months ended in Mar. 2026 was $4.16 Mil. Exagen's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $7.10 Mil.
Hence, Exagen's Days Payable for the
three
months ended in Mar. 2026 was 53.41.
The historical rank and industry rank for Exagen's Days Payable or its related term are showing as below:
XGN'
s Days Payable Range Over the Past 10 Years
Min: 26.73 Med: 49.16 Max: 76.98
Current: 48.38
During the past 13 years, Exagen's highest Days Payable was 76.98. The lowest was 26.73. And the median was 49.16.
XGN's Days Payable is ranked worse than 63.16% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs XGN: 48.38
Exagen's Days Payable
declined
from Mar. 2025 (61.88) to Mar. 2026 (53.41).
It may suggest that Exagenaccelerated paying its suppliers.
Exagen Days Payable Related Terms
Exagen Days Payable Historical Data
* Premium members only.
The historical data trend for Exagen's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Exagen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exagen Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's Days Payable distribution charts can be found below:
* The bar in red indicates where Exagen's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Exagen's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exagen (XGN) has a Days Payable of 53.41 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Exagen and its competitors. This is near median its historical median of 49.16. Over the past decade, Exagen's Days Payable has ranged from 26.73 to 76.98. According to the industry distribution chart, Exagen ranks #120 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 63.2%.
Is Exagen's Days Payable too high?
Exagen's current Days Payable of 53.41 is near median its 10-year median of 49.16. Over the past 10 years, this metric has ranged from a low of 26.73 to a high of 76.98. The Medical Diagnostics & Research industry median Days Payable is 67.28. Exagen's value of 53.41 is 20.6% below this industry median. Based on the distribution chart, Exagen ranks #120 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Exagen has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exagen's Days Payable compare to BNR and IMDX?
According to the Medical Diagnostics & Research industry distribution chart, Exagen ranks #120 out of 190 companies for Days Payable. This places Exagen in the lower half of its industry. The industry median Days Payable is 67.28. Exagen's value of 53.41 is 20.6% below this benchmark. Historically, Exagen's own Days Payable has ranged from 26.73 to 76.98 over the past decade. While the company's 10-year median is 49.16 vs. the industry median of 67.28, Exagen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exagen's current Days Payable of 53.41 is 20.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Exagen and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exagen's current Days Payable is 53.41, which is near median its own 10-year median of 49.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exagen stock overvalued right now?
Based on GuruFocus' analysis, Exagen (XGN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $4.54 — trading 51.3% above its estimated fair value. The current Days Payable is 53.41, which is near median its 10-year median of 49.16 and 20.6% below the Medical Diagnostics & Research industry median of 67.28. Exagen's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Exagen (XGN), the current Days Payable is 53.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exagen (XGN) Overvalued in 2026?
Based on GuruFocus' analysis, Exagen stock appears to be overvalued.
The current stock price of $4.54 is trading 51.3% above its estimated GF Value™ of $3.00.
GuruFocus considers Exagen to be Significantly Overvalued.
Key valuation signals for XGN:
Days Payable: 53.41 (near median its 10-year median of 49.16)
GF Value™: $3.00 vs. price of $4.54 (51.3% above fair value)
Industry Position: 20.6% below the Medical Diagnostics & Research median (#120 of 190)
No single metric tells the full story. See the XGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
60GF Score
Get the complete analysis for XGN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGN has been successfully added to your 
